RETATRUTIDE 10MG

Retatrutide is one of the most promising new weight-loss and metabolic health drugs currently in clinical development. Unlike existing GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) or dual agonists like tirzepatide (Mounjaro, Zepbound), Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. This unique mechanism has shown unprecedented results in early clinical trials, with participants losing over 24% of their body weight in less than a year at the highest studied doses.

Retatrutide (also known as LY-3437943) is an experimental medication developed by Eli Lilly that is being studied as a next-generation treatment for obesity, overweight, and related metabolic conditions such as type 2 diabetes. It represents a new class of therapies called “triple agonists,” meaning it simultaneously activates three key hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This combined activity helps regulate appetite, improve insulin sensitivity, slow gastric emptying to promote fullness, and enhance fat burning.

Key Points:

• Retatrutide is given as a once-weekly subcutaneous injection.
• Stepwise escalation is critical to reduce gastrointestinal intolerance.
• Most participants in trials reached 8–12 mg weekly, which delivered the strongest results
• Dosing protocols may be refined in Phase 3 and post-approval, but gradual titration will remain the standard.

Reconstitute: Add 2mL bacteriostatic water (40 units = 2mg)

Typical weekly range: 2-8 mg once weekly (gradual escalation over 8–12 weeks).

Weeks 1-4 : 2mg = 40 units
Weeks 5-8 : 4mg = 80 units
Weeks 9-12 :  6mg = 120 units
Weeks 13+ : 8mg = 160 units

Common Side Effects :

Across Phase 2 trials, participants experienced dose-dependent GI symptoms that are characteristic of GLP-1 receptor agonists:

Nausea (most frequent, especially during dose escalation)
Vomiting (typically mild to moderate, subsiding with continued use)
Diarrhea and constipation (fluctuating depending on individual tolerance)
Abdominal discomfort (transient and often improved over time)